The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment)

   Single User - $3,995
   Site License (one location, 10 users) - $5,995
   Corporate License - $7,990

Published Aug 9, 2013 | 230 Pages | Pub ID: KLI5094606

This  Kalorama Information report  The Market for Hospital-Acquired Infection Control (Sterilization, Cleaning, Testing, Treatment) focuses on the market for preventing, testing and treating infections in the healthcare environment.

Given the cost of hospital-acquired and healthcare-associated infections (HAIs), demand has increased for solutions that can help the healthcare industry reduce infections and the costs associated with them. The U.S. Centers for Disease Control and Prevention (CDC) estimates that around 1 in 20 or 5% of hospitalized patients will contract an HAI.   Treatment and testing guidelines for the following diseases are covered:

Acinetobacter Baumannii Clostridium Difficile Hospital-Acquired Pneumonia Pseudomonas Aeruginosa Staphylococcus Aureus Methicillin-resistant Staphylococcus Aureus (MRSA) Vancomycin-Intermediate/Resistant Staphylococcus Aureus Tuberculosis Urinary Tract Infections Vancomycin-resistant Enterococcus Ventilator-Associated Pneumonia
Worldwide, the rate of nosocomial infections is between 3.5% and 12% of admissions in developed regions. This has created a market opportunity for companies that can test for, treat and help prevent these infections.

Fighting the scourge of HAIs requires a multi-faceted approach.  The report will provide a market analysis for each of the three areas:

Prevention (Medical Device/Instrument Sterilization, Wide-Area Sterilization, Other)
 Testing Markets for HAI (C.Diff, MRSA, Other)
Treatment Markets

For each segment, the report breaks out the market by major regions (United States, Europe, ROW) and the emerging markets.  The infection control market is a stable one for companies involved in these areas. As long as there are infections there will always be a need for controlling these infections. It is a fact that diseases evolve and that new approaches to preventing, diagnosing and treating will be required for the long-term.

The analysis presented in this report is based on data from a combination of company, government, industry, institutional and private sources. It includes information from extensive literature reviews and discussions with experts in the field, including microbiologists, pathologists, hospital authorities, reimbursement specialists, research scientists, business development managers and marketing managers.

The majority of competitive participation for Hospital-Acquired Infection control and is in the United States and Europe. However, competition is steadily escalating in the United States and Europe, which is encouraging more participation in other areas such as Asia and Latin America. Companies included in this report are:

    Advanced Sterilization Products
    Becton Dickinson
    Belimed AG
    Merck & Co.
    Sakura Seiki

In this report,  {{key}} appears {{searchResults.reportMatchCounts[value]}} times